NCT01039025 is a Phase 2 clinical trial of Topotecan in Myeloma, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT01039025?

NCT01039025 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT01039025?

Interventions in NCT01039025: Topotecan, Cyclophosphamide, Melphalan, Peripheral Blood Stem Cells.

Is NCT01039025 still recruiting?

NCT01039025 is currently completed. Last updated 7 November 2018.

Last reviewed 2018-11-07 · How we verify

NCT01039025

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma

Completed Phase 2 Last updated 7 November 2018

What this trial tests

Phase 2 trial testing Topotecan in Myeloma in 60 participants. Completed in 19 May 2006.

Timeline

18 February 2002

Primary endpoint
19 May 2006

19 May 2006

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	18 February 2002
Primary completion	19 May 2006
Estimated completion	19 May 2006
Sites	1 location across United States

Drugs / interventions tested

Topotecan (topotecan) — full drug profile →
Cyclophosphamide (cyclophosphamide) — full drug profile →
Melphalan (melphalan) — full drug profile →
Peripheral Blood Stem Cells — full drug profile →

Conditions studied

Myeloma — all drugs for Myeloma →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

Under 70, any sex, with Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determine the efficacy of high-dose topotecan, cyclophosphamide and melphalan in patients with Multiple Myeloma.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma.
Kazmi SM, Saliba RM, Donato M, Wang M, et al · · 2011 · cited 20× · PMID 20581887 · DOI 10.1038/bmt.2010.160

Verify or expand the search:

Other trials of Topotecan

Trials testing the same drug.

NCT07437963 — Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatmen · Phase 1, PHASE2 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
NCT07321912 — Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma · Phase 2 · not yet recruiting
NCT06425419 — The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy · Phase 1 · not yet recruiting

Other recruiting trials for Myeloma

Currently open trials in the same condition.

NCT06487247 — HEME Home Transfusion Program · NA · recruiting
NCT07106671 — A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma · Phase 2 · recruiting
NCT07052916 — A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties · NA · recruiting
NCT07202078 — Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig) · Phase 2, PHASE3 · recruiting
NCT07202091 — Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig) · Phase 2, PHASE3 · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01039025 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 7 November 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01039025.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing